MV BioTherapeutics SA news
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 6thMicrobiome Movement – Drug Development Summit Europe 2022 in London during January 25th-27th, 2022.
The presentation has been included in stream A titled &ldqu
MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant.
Malcisbo and MV Bio have previously
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 5th Microbiome Movement – Drug Development Summit Europe 2021 being held virtually during January 27th-29th, 2021.
The presentation has been included in the morning str
MV BioTherapeutics is participating at this important annual event and virtually meet potential investors and licensing partners.
Please contact
MV BioTherapeutics participated for the first time to the international event Bio Digital 2020 presenting the company, the pipeline to over 50 companies.
“We weren’t sure about the potential success when we applied to the Swiss Pavillon wi